leflunomide has been researched along with Abnormalities, Drug-Induced in 14 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Maternal exposure to leflunomide during pregnancy was not associated with statistically significant increased risk of MCMs, prematurity, LBW or spontaneous abortions." | 7.88 | Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. ( Bérard, A; Colilla, S; Shui, I; Zhao, JP, 2018) |
| "All 16 of the pregnancies with leflunomide exposure during pregnancy and 27 (93%) of the pregnancies with exposure prior to conception resulted in liveborn infants." | 7.78 | Pregnancy outcome in women exposed to leflunomide before or during pregnancy. ( Braddock, SR; Cassina, M; Chambers, CD; Jimenez, JL; Johnson, DL; Jones, KL; Luo, YJ; Mirrasoul, N; Robinson, LK; Salas, E; Xu, R, 2012) |
| "Leflunomide is a new and effective disease-modifying antirheumatic drug." | 5.31 | Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes. ( Koren, G; Kozer, E; Moretti, ME, 2001) |
| "The widely accepted standard therapy for cutaneous sarcoidosis includes corticosteroids, antimalarials, and methotrexate." | 4.84 | Cutaneous sarcoidosis therapy updated. ( Badgwell, C; Rosen, T, 2007) |
| "Maternal exposure to leflunomide during pregnancy was not associated with statistically significant increased risk of MCMs, prematurity, LBW or spontaneous abortions." | 3.88 | Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. ( Bérard, A; Colilla, S; Shui, I; Zhao, JP, 2018) |
| "All 16 of the pregnancies with leflunomide exposure during pregnancy and 27 (93%) of the pregnancies with exposure prior to conception resulted in liveborn infants." | 3.78 | Pregnancy outcome in women exposed to leflunomide before or during pregnancy. ( Braddock, SR; Cassina, M; Chambers, CD; Jimenez, JL; Johnson, DL; Jones, KL; Luo, YJ; Mirrasoul, N; Robinson, LK; Salas, E; Xu, R, 2012) |
| "Leflunomide is an immunosuppressant drug displaying teratogenicity in mice, rats, and rabbits." | 1.35 | Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine. ( Fukushima, R; Hirashiba, M; Hishikawa, A; Kanamori, S; Kaneto, M; Kitagawa, H; Muranaka, R, 2009) |
| "Leflunomide has inhibitory effects on dihydroorotate-dehydrogenase activity and protein tyrosine kinase activity." | 1.35 | Critical periods for the teratogenicity of immune-suppressant Leflunomide in mice. ( Fukushima, R; Hirashiba, M; Hishikawa, A; Kanamori, S; Kaneto, M; Kitagawa, H; Muranaka, R, 2009) |
| "Leflunomide is a new and effective disease-modifying antirheumatic drug." | 1.31 | Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes. ( Koren, G; Kozer, E; Moretti, ME, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Pfaller, B | 1 |
| Pupco, A | 1 |
| Leibson, T | 1 |
| Aletaha, D | 1 |
| Ito, S | 1 |
| Hammad, I | 1 |
| Porter, TF | 1 |
| Weber-Schoendorfer, C | 1 |
| Beck, E | 1 |
| Tissen-Diabaté, T | 1 |
| Schaefer, C | 1 |
| Bérard, A | 1 |
| Zhao, JP | 1 |
| Shui, I | 1 |
| Colilla, S | 1 |
| Cassina, M | 2 |
| Cagnoli, GA | 1 |
| Zuccarello, D | 1 |
| Di Gianantonio, E | 1 |
| Clementi, M | 1 |
| Fukushima, R | 2 |
| Kanamori, S | 2 |
| Hirashiba, M | 2 |
| Hishikawa, A | 2 |
| Muranaka, R | 2 |
| Kaneto, M | 2 |
| Kitagawa, H | 2 |
| Chambers, CD | 3 |
| Johnson, DL | 2 |
| Robinson, LK | 1 |
| Braddock, SR | 1 |
| Xu, R | 1 |
| Jimenez, JL | 1 |
| Mirrasoul, N | 1 |
| Salas, E | 1 |
| Luo, YJ | 1 |
| Jones, KL | 2 |
| Viktil, KK | 1 |
| Engeland, A | 1 |
| Furu, K | 1 |
| Badgwell, C | 1 |
| Rosen, T | 1 |
| Chambers, C | 1 |
| Koren, G | 2 |
| Tutuncu, ZN | 1 |
| Johnson, D | 1 |
| Kozer, E | 1 |
| Moretti, ME | 1 |
| Lyons Jones, K | 1 |
4 reviews available for leflunomide and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
A critical review of the reproductive safety of Leflunomide.
Topics: Abnormalities, Drug-Induced; Animals; Female; Humans; Immunosuppressive Agents; Leflunomide; Pregnan | 2020 |
An Update on Biologic Agents During Pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humani | 2020 |
Cutaneous sarcoidosis therapy updated.
Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Allopurinol; Animals; Anti-Inflammatory Agents | 2007 |
Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study.
Topics: Abnormalities, Drug-Induced; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprin | 2007 |
10 other studies available for leflunomide and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Leflunomide - A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Adverse Drug Reaction Reporti | 2017 |
Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Humans; Inf | 2018 |
Human teratogens and genetic phenocopies. Understanding pathogenesis through human genes mutation.
Topics: Abnormalities, Drug-Induced; Angiotensin-Converting Enzyme Inhibitors; Animals; Female; Fetal Diseas | 2017 |
Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine.
Topics: Abnormalities, Drug-Induced; Animals; Dihydroorotate Dehydrogenase; Embryonic Development; Female; F | 2009 |
Critical periods for the teratogenicity of immune-suppressant Leflunomide in mice.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adjuvants, Immunologic; Animals; Critical Peri | 2009 |
Value of the small cohort study including a physical examination for minor structural defects in identifying new human teratogens.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antidepressive Agents; Arthritis, Rheumatoid; Carbamaz | 2011 |
Pregnancy outcome in women exposed to leflunomide before or during pregnancy.
Topics: Abnormalities, Drug-Induced; Antirheumatic Agents; Chondrodysplasia Punctata; Ductus Arteriosus, Pat | 2012 |
Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers.
Topics: Abnormalities, Drug-Induced; Adalimumab; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antir | 2012 |
Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes.
Topics: Abnormalities, Drug-Induced; Adult; Arthritis, Rheumatoid; Female; Half-Life; Humans; Immunosuppress | 2001 |
Monitoring leflunomide (Arava) as a new potential teratogen.
Topics: Abnormalities, Drug-Induced; Arthritis, Rheumatoid; Female; Humans; Infant, Newborn; Isoxazoles; Lef | 2002 |